Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress

详细信息    查看全文

• 作者：Yosra M. Magdy^a ; ^{y_yosra@hotmail.com} ; Omnyah A. El-Kharashi^a ; ^{omnyah2011@gmail.com} ; Enas S. Nabih^b ; ^{enassamer@hotmail.com} ; Safaa M. Shaker^c ; ^{safashalaby@yahoo.com} ; Lobna F. Abd-Elaziz^a ; ^{lobna-pharma@hotmail.com} ; Sawsan Aboul-Fotouh^a ; ^{sawsanaf2005@yahoo.com}
• 关键词：Behavior ; Chronic restraint stress ; Depression ; JNK ; Metformin ; NASH ; Rat ; Sitagliptin
• 刊名：Biomedicine & Pharmacotherapy
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：85
• 期：Complete
• 页码：225-238
• 全文大小：4254 K
• 卷排序：85

文摘

Depression and non-alcoholic steatohepatitis (NASH) are highly co-morbid, and hepatic JNK pathway may be involved in their relation.AimTo evaluate the impact of depression on NASH through the involvement of JNK1 and to assess the effect of sitagliptin and metformin on hepatic JNK1 expression in both NASH and NASH associated with depression.MethodsEight groups of male Wistar rats were used: naïve rats, non-stressed NASH, non-stressed NASH sitagliptin treated, non-stressed NASH metformin treated, stressed, stressed NASH untreated, stressed NASH sitagliptin treated and stressed NASH metformin treated. Behavioral, biochemical, molecular and histopathological studies were performed.ResultsNon-stressed NASH group showed depressive like symptoms, disturbed glucose homeostasis, impairment of liver functions, decrease adiponectin and increase malondialdehyde, which were aggreviated by stress.Sitagliptin produced significant improvement compared to metformin regarding biochemical and histopathological parameters. Furthermore, sitagliptin significantly decreased expression of hepatic JNK1 in both stressed and non-stressed rats. All these changes were accompanied by significant improvement of behavioral changes.ConclusionsThe link between NASH and depression raised the role of JNK activation through increase expression of JNK1. Since sitagliptin was associated with preferable effects than metformin, therefore, it is potentially preferred in the management of either NASH or NASH associated with depression.